Internship
Legend Biotech
1,001-5,000 employees
Develops and commercializes cell therapies
No salary listed
Somerset County, NJ, USA
This is a hybrid position, which may require some in-office days.
- Rising Junior or Senior pursuing a Bachelor’s or Master’s degree in Biomedical Engineering or related degree
- Desire to work in cell and gene therapy manufacturing and analytical automation development
- Strong verbal and written communication skills
- Demonstrated leadership qualities and problem-solving skills
- Positive attitude, team-oriented, adaptive to change, and collaborative
- Actively involved in campus or community activities and organizations, preferably in leadership roles.
- Prior lab experience is a plus.
- Join the cell and gene therapy manufacturing development automation team at Legend Biotech
- Focus on qualifying and enhancing automated and closed systems used in cell and gene therapy manufacturing
- Work closely with automation development Scientists
- Conduct experiments and validation studies for new and innovative automation for high-throughput manufacturing process validation studies
- Gain hands-on experience in cell and gene therapy drug product manufacturing development focused on closed systems and automation.
- Prior lab experience is a plus.
Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers affecting the blood and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company focuses on personalized medicine, which tailors therapies to individual patients. They not only discover and develop new therapies but also bring them to market, generating revenue through licensing and sales, such as their CAR-T therapies that modify patients' own cells to combat cancer. Legend Biotech stands out by its commitment to transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Franklin Township, New Jersey
Founded
2014
Simplify's Take
What believers are saying
- $150M investment in Belgium facility shows commitment to expanding production capabilities.
- Alan Bash's appointment strengthens leadership in CAR-T therapy market.
- New R&D facility in Philadelphia focuses on next-generation cell therapies.
What critics are saying
- Increased competition from Amgen's Imdelltra could impact market share.
- Collaboration with Multiply Labs may face challenges in scaling up production.
- Expansion of R&D facilities requires significant investment, potentially straining resources.
What makes Legend Biotech unique
- Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
- The company is technology agnostic, exploring multiple platforms for effective treatments.
- Legend Biotech's business model includes discovery, development, and commercialization of therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms.
Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.
Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr
With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.